Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years?

doi:10.3748/wjg.v20.i5.1192

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 5

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (31797)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

1563

WORD

452

HTML

25654

Figures (1-1)

266

Tables (1-2)

218

Sum=28153

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1539

Download

2105

Sum=3644

Feb 7, 2014 (publication date) through Nov 18, 2024

Times Cited of This Article

Times Cited (275)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Feb 7, 2014; 20(5): 1192-1210
Published online Feb 7, 2014. doi: 10.3748/wjg.v20.i5.1192

Table 1 Evidence for the role of specific major pathogens in the aetiopathogenesis of inflammatory bowel disease in the last decade n (%)

Year	Pathogen	Disease	Sample type	Detection rate			Reference
Year	Pathogen	Disease	Sample type	CD	UC	Control	Reference
2003	MAP	CD	Tissue	34/37 (92)		9/34 (26)	[85]
2003	MAP	CD and UC	Tissue	0/24 (0)	1/28 (4)	6/19 (32)	[94]
2003	Helicobacter	CD and UC	Tissue	0/9 (0)	0/11 (0)	0/10 (0)	[109]
2004	MAP	CD and UC	Blood	107/283 (37.8)	50/144 (34.7)	135/402 (33.6)	[92]
2004	MAP	CD and UC	Blood	13/28 (46)	4/9 (45)	3/15 (20)	[86]
2004	H. pylori	UC	Tissue	8/42 (19)		7/74 (9.5)	[110]
2004	Helicobacter	CD and UC	Tissue	1/25 (4)	5/33 (15.2)	0/29 (0)	[111]
2004	Helicobacter	CD and UC	Tissue	0/30 (0)	0/26 (0)	0/25 (0)	[112]
2004	EHH	CD and UC	Tissue	3/25 (12)	3/18 (17)	1/23 (4)	[113]
	H. pullorum			2/25 (8)	0/18 (0)	1/23 (4)
	H. fennelliae			1/25 (4)	3/18 (17)	0/23 (0)
	H. pylori			8/25 (32)	5/18 (28)	14/23 (61)
2004	Helicobacter	CD, UC and IC	Tissue	0/11 (0)	1/20 (5)	0/37 (0)	[114]
2004	E. coli	CD and UC	Tissue	11/14 (79)	8/21 (38)	10/24 (42)	[156]
2004	AIEC	CD and UC	Tissue	10/14 (71)	10/21 (48)	7/24 (29)	[156]
2004	AIEC	CD	Tissue	7/63 (11.1)		1/16 (6.3)	[154]
2004	E. coli	CD	Tissue	12/15 (80)		1/10 (10)	[158]
2006	E. coli	CD and UC	Tissue	9/12 (75)	7/7 (100)	2/8 (25)	[159]
2007	AIEC	CD and UC	Tissue	8/13 (61.5)	11/19 (57.9)	4/15 (26.7)	[160]
2008	Helicobacter	CD	Faeces	17/29 (59)		1/11 (9)	[115]
	EHH			11/29 (38)		1/11 (9)
	H. pylori			6/29 (21)		0/11 (0)
	H. trogontum			4/29 (14)		1/11 (9)
	H. canis			5/29 (17)		0/11 (0)
	H. bilis			4/29 (14)		0/11 (0)
	H. cinaedi			1/29 (3)		0/11 (0)
2009	AIEC	CD	Tissue	14/27 (51.9)		4/24 (16.7)	[155]
2009	Helicobacter	CD	Tissue	32/73 (43.8)		43/92 (46.7)	[116]
	EHH			18/73 (24.7)		16/92 (17.4)
	H. pylori			29/73 (39.7)		39/92 (42.4)
	H. pullorum			8/73 (11)		6/92 (6.5)
	H. canndensis			10/73 (13.7)		10/92 (10.9)
2009	Campylobacter	CD	Tissue	27/33 (82)		12/52 (23)	[131]
	C. concisus			17/33 (51)		1/52 (2)
	C. showae			3/33 (9)		0/52 (0)
	C. hominis			2/33 (6)		2/52 (4)
	C. gracilis			2/33 (6)		0/52 (0)
	C. rectus			1/33 (3)		2/52 (4)
	C. jejuni			1/33 (3)		3/52 (6)
	C. ureolyticus			1/33 (3)		2/52 (4)
2010	Helicobacter	CD	Tissue	32/77 (41.6)		23/102 (22.5)	[117]
	EHH			18/77 (23.4)		12/102 (11.8)
	H. pylori			14/77 (18.2)		11/102 (10.8)
	H. bilis			1/77 (1.3)		1/102 (1.0)
	H. canis			2/77 (2.6)		0/102 (0.0)
	H. hepaticus			2/77 (2.6)		2/102 (2.0)
	H. trogontum			5/77 (6.5)		4/102 (3.9)
2010	Campylobacter	CD	Faeces	39/54 (72)		10/33 (10)	[132]
2010	C. concisus	CD	Faeces	35/54 (65)		11/33 (33)	[132]
2010	C. concisus	CD and UC	Saliva	13/13 (100)	5/5 (100)	57/59 (97)	[136]
2011	Helicobacter	UC	Tissue		32/77 (42)	11/59 (19)	[118]
	EHH				30/77 (39)	2/59 (3)
	H. pylori				2/77 (3)	9/59 (15)
2011	C. concisus	CD, UC and IC	Tissue	8/12 (66.7)	3/8 (37.5)	11/26 (42.3)	[133]
2011	Campylobacter	UC	Tissue		51/69 (73.9)	15/65 (23.1)	[135]
	C. concisus				23/69 (33.3)	7/65 (10.8)
	C. ureolyticus				15/69 (21.7)	2/65 (10.8)
	C. hominis				14/69 (20.3)	5/65 (7.7)
	C. curvus				3/69 (4.3)	4/65 (6.2)
	C. showae				4/69 (5.8)	0/65 (0)
	C. jejuni				2/69 (2.9)	0/65 (0)
	C. gracilis				1/69 (1.4)	0/65 (0)
2011	Campylobacter	CD and UC	Tissue	12/15 (80)	11/13 (85)	18/33 (48)	[134]
	C. concisus			10/15 (67)	9/13 (69)	12/33 (36)
	C. showae			1/15 (7)	2/13 (15)	2/33 (6)
	C. hominis			1/15 (7)	1/13 (8)	3/33 (9)
	C. ureolyticus			2/15 (13)	1/13 (8)	2/33 (6)
	C. gracilis			1/15 (7)	1/13 (8)	0/33 (0)
	C. rectus			0/15 (0)	1/13 (8)	0/33 (0)
	C. jejuni			1/15 (7)	0/13 (0)	0/33 (0)
2012	AIEC	CD and UC	Tissue	1/17 (5.9)	1/10 (10)	0/23 (0)	[166]
2013	Helicobacter	CD and UC	Tissue	4/29 (13.8)	1/13 (7.7)	5/42 (11.9)	[119]
	H. brantae			1/59 (3.4)	0/13 (0)	0/42 (0)
	H. hepaticus			1/59 (3.4)	0/13 (0)	0/42 (0)
2013	Campylobacter	CD and UC	Tissue	22/29 (75.9)	9/13 (69)	32/42 (76.2)	[119]
	C. concisus			13/29 (44.8)	4/13 (30.8)	16/42 (38.1)
	C. curvus			2/29 (6.9)	0/13 (0)	3/42 (7.1)
	C. gracilis			1/29 (3.4)	0/13 (0)	2/42 (4.8)
	C. hominis			9/29 (31.0)	5/13 (38.5)	14/42 (33.3)
	C. rectus			0/29 (0)	0/13 (0)	4/42 (9.5)
	C. showae			9/29 (31.0)	5/13 (38.5)	9/42 (21.4)
	C. ureolyticus			0/29 (0)	0/13 (0)	2/42 (4.8)

CD: Crohn’s disease; UC: Ulcerative colitis; IC: Indeterminate colitis; IBD: Inflammatory bowel disease; MAP: Mycobacterium avium subspecies paratuberculosis; EHH: Enterohepatic Helicobacter; E. coli: Escherichia coli; AIEC: Adherent-invasive E. coli.

Table 2 Probiotics and prebiotics in inflammatory bowel disease

Active component	Study	Design	n	Duration	Intervention	Result	Reference
Lactobacillus	CD remission	RCT	98	6 mo	Lactobacillus johnsonii LA1 4 × 10⁹ cfu/d	No difference	[184]
	IBD		40	1 mo	Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 supplemented yogurt	Anti-inflammatory effects	[185]
Bifidobacterium	Active UC	RCT	20	12 wk	Bifido-fermented milk [B. breve, B. bifidum and acidophilus] (1 × 10¹⁰) or placebo	Decreased clinical activity (P < 0.05) decreased endoscopic/histological scores (P < 0.01)	[186]
	Active UC	Open label	12	4 wk	BGS 4.5 g/d	Decrease in clinical activity index (P < 0.01) and endoscopic scores (P < 0.05)	[187]
	C57BL/6 mice	Experimental	16	3 d	B. bifidum S17	Decrease in microscopic inflammation and reduction in inflammatory cytokines	[188]
E. coli Nissle 1917	UC remission		327	12 mo	200 mg E. coli Nissle 1917 or 1500 mg mesalazine/d	E. coli Nissle 1917 was equivalent to mesalazine in maintaining remission	[189]
VSL#3	UC remission	Open label	34	6 wk	VSL#3, 3.6 × 10¹², bacteria/d	ITT analysis demonstrated remission in 18/34 and response in 8/34	[190]
	Active UC	RCT	29	12 mo	VSL#3 450-1800 billion bacteria/d	Remission was achieved in 13/14 VSL#3 and 4/15 placebo (P < 0.001)	[191]
						Relapses within 1 yr of followup occurred in 3/14 VSL#3 and 11/15 placebo
						Endoscopic and histological score were significantly lower in VSL#3 vs placebo (P < 0.05)
Inulin	Active UC	RCT	19	2 wk	3 g/d mesalazine and either 12 g/d oligofructose-enriched inulin or placebo	Dyspeptic symptoms scale decreased significantly and an early reduction of calprotectin was observed in oligofructose-enriched inulin group	[202]
	Pouchitis	RCT	20	3 wk	24 g/d inulin or placebo	Reduction in inflammation, increase butyrate conc and decreased inflammation associated factors	[203]
Inulin and FOS	HLA-B27 rat model IBD			12 wk	8 g/kg body weight inulin or FOS	FOS increased Bifidobacterium spp. FOS and inulin reduced Clostridium cluster XI and C. difficile toxin gene expression correlating with a reduction of chronic intestinal inflammation	[204]
FOS	Active CD	RCT	103	4 wk	15 g/d FOS or placebo	No clinical benefit, despite impacting on DC function	[205]
	Active CD	Open label	10	3 wk	15 g/d	Significant reduction in Harvey Bradshaw index (P < 0.01) significant increase in faecal bifidobacteria conc. (P < 0.001) and modifies DC function	[206]

CD: Crohn’s disease; UC: Ulcerative colitis; IBD: Inflammatory bowel disease; RCT: Randomized control trial; FOS: Fructooligosaccharides; E. coli: Escherichia coli.

Citation: Hold GL, Smith M, Grange C, Watt ER, El-Omar EM, Mukhopadhya I. Role of the gut microbiota in inflammatory bowel disease pathogenesis: What have we learnt in the past 10 years? World J Gastroenterol 2014; 20(5): 1192-1210
URL: https://www.wjgnet.com/1007-9327/full/v20/i5/1192.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i5.1192